NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal

Clostridium botulinum neurotoxin type A for treating sialorrhoea associated with neurological conditions ID1150

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
 Merz Pharma UK (clostridium botulinum neurotoxin type A) Patient/carer group Action Cerebral Palsy Brain and Spine Foundation Different Strokes Leonard Cheshire Disability Motor Neurone Disease Association MS-UK Multiple Sclerosis National Therapy Centres Multiple Sclerosis Society Multiple Sclerosis Trust Muslim Council of Britain Neurological Alliance Parkinson's UK Scope Stroke Association South Asian Health Foundation Specialised Healthcare Alliance The Brain Charity The Pace Centre 	 General All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare Products Regulatory Agency Multiple Sclerosis Wales National Association of Primary Care National Pharmacy Association Neurological Alliance of Scotland NHS Alliance NHS Confederation Scottish Medicines Consortium Wales Neurological Alliance Welsh Health Specialised Services Committee
 Professional groups Association of British Neurologists Association of Neuroscience Nurses British Association of Stroke Physicians British Geriatrics Society British Neuropathological Society British Neuropsychiatry Association British Paediatric Neurology 	 Comparator companies Accord Healthcare (glycopyrronium bromide) Concordia International (glycopyrronium bromide) Genus Pharmaceuticals (trihexyphenidyl hydrochloride) Martindale Pharma (glycopyrronium bromide, transdermal hyoscine hydrobromide)

Matrix for the proposed single technology appraisal of clostridium botulinum neurotoxin type A for treating sialorrhoea associated with neurological conditions ID1150 Issue date: November 2018

Consultees Commentators (no right to submit or appeal) Association (BPNA) Proveca (glycopyrronium bromide) British Society of Rehabilitative Medicine Relevant research groups **Brain Research Trust** Chartered Society of Physiotherapy College of Occupational Therapists British Neurological Research Trust Institute of Neurology Cochrane Cystic Fibrosis and Genetic Neuromodulation Society of UK and Disorders Group Ireland Cochrane Movement Disorders Group Primary Care Neurology Society Cochrane Multiple Sclerosis and Rare Royal College of General Practitioners Diseases of the Central Nervous Royal College of Nursing System Group Cochrane Stroke Group Royal College of Pathologists Royal College of Physicians MRC Clinical Trials Unit National Hospital for Neurology and Royal College of Speech and Neurosurgery Language Therapists National Institute for Health Research Royal Pharmaceutical Society The Cure Parkinson's Trust Royal Society of Medicine The Society for Research in Therapists in MS Rehabilitation **UK Health Forum** UK Parkinson's Disease Consortium **UK Clinical Pharmacy Association** Wellcome Trust **UK Multiple Sclerosis Specialist Nurses Association** Associated Public Health Groups • Public Health England Others Public Health Wales Department of Health NHS Canterbury and Coastal CCG NHS England NHS High Weald Lewes Havens CCG

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Matrix for the proposed single technology appraisal of clostridium botulinum neurotoxin type A for treating sialorrhoea associated with neurological conditions ID1150 Issue date: November 2018

Welsh Government

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-company commentators are invited to nominate clinical specialists or patient experts.

Matrix for the proposed single technology appraisal of clostridium botulinum neurotoxin type A for treating sialorrhoea associated with neurological conditions ID1150

¹Non-company consultees are invited to submit statements relevant to the group they are representing.